HCA Healthcare, Inc.
Close on Oct 19, 2026
- Market cap
- $103.10B
- P/E (TTM)
- 15.6
- Dividend yield
- 0.63%
About HCA Healthcare
Services-General Medical & Surgical Hospitals, NEC, SIC 8062
HCA Healthcare, Inc. is a healthcare services company that provides medical and outpatient care. The organization operates general acute care hospitals delivering medical and surgical specialties including cardiology, emergency medicine, oncology, neurosurgery, orthopedics, obstetrics, and intensive care. Its outpatient network encompasses freestanding ambulatory surgery centers, freestanding endoscopy and emergency care facilities, urgent care clinics, diagnostic centers, physician practices, home health agencies, and hospices. In addition, the company runs behavioral hospitals offering mental health and substance abuse treatment, along with specialized rehabilitation facilities. Its customer base consists of patients receiving care funded via private insurers, Medicare, Medicaid, managed care plans, and direct payments.
As of December 31, 2025, the company's network includes 190 hospitals, 121 freestanding ambulatory surgery centers, and 31 freestanding endoscopy centers across 19 U.S. states and England. Its principal executive offices are situated in Nashville, Tennessee.
Summary of the business section of HCA Healthcare's latest annual report, written by StockData.
Company profile
Company
- Legal name
- HCA Healthcare, Inc.
- Founded
- 1968
- Headquarters
- Nashville, TN
- Address
- One Park Plz 37203
- Phone
- (615) 344-9551
- Website
- hcahealthcare.com
- Employees
- 320,000, Dec 31, 2025
- Industry
- Services-General Medical & Surgical Hospitals, NEC
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Nashville, Tennessee, United States of America
Stock & identifiers
- Ticker
- HCA
- Exchange
- NYSE
- Shares outstanding
- 217M, Jul 24, 2026
- Public float
- $63.27B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 860730
- CUSIP
- 40412C101
- ISIN
- US40412C1018
- LEI
- 529900PH4ZGUH2MNEU89
- EIN
- 27-3865930
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Samuel N. Hazen | CEO, Director | 1,403,617 |
| Michael J. Schlosser | EVP and Chief Clinical Officer | 7,121 |
| Michael R. McAlevey | EVP & Chief Legal & Admin Off. | 10,990 |
| Mike A. Marks | EVP and CFO | 73,076 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 35,581 |
| Christopher F. Wyatt | SVP & Controller | 44,379 |
| Jon M. Foster | EVP and COO | 194,516 |
| Jennifer Berres | SVP & Chief Human Res. Officer | 16,003 |
| Erica Rossitto | SVP & Chief Nurse Executive | 10,825 |
| Sammie S. Mosier | SVP & Chief Nurse Executive | 11,340 |
| Kathleen M. Whalen | SVP & Chief Ethics Officer | 9,454 |
| Phillip G. Billington | SVP-Internal Audit Services | 52,702 |
| Erol R. Akdamar | Group President | 127,340 |
| William R. Frist | Director | 69,256,716 |
| Hugh F. Johnston | Director | 4,475 |
| Nancy Ann Deparle | Director | 21,910 |
| Michael W. Michelson | Director | 23,385,908 |
| John Chidsey | Director | 1,333 |
| Thomas F. Frist Iii | Director | 68,855,888 |
| Wayne Joseph Riley | Director | 15,029 |
| Andrea B. Smith | Director | 4,748 |
| Robert J. Dennis | Director | 26,601 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Hazen | $26.46M | $78.24M | $8.19M | $296 | $148 |
| FY2024 Hazen | $23.80M | $40.15M | $6.12M | $189 | $129 |
| FY2023 Hazen | $21.32M | $23.59M | $6.86M | $169 | $126 |
| FY2022 Hazen | $14.64M | $9.58M | $5.17M | $149 | $124 |
| FY2021 Hazen | $20.64M | $84.57M | $6.00M | $158 | $126 |
| FY2020 Hazen | $30.40M | $30.45M | $7.04M | $112 | $113 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“Our workforce consists of approximately 320,000 employees (as of December 31, 2025), including approximately 90,000 part-time and PRN employees (references herein to “employees” or “colleagues” refer to employees of our affiliates).”
Corporate history
Events identified from SEC filings